ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1083

Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment

Sabina Oreska1, Hana Storkanova2, Maja Spiritovic3, Barbora Hermankova4, Michal Vrablik5, Karel Pavelka6, Ladislav Šenolt6, Heřman Mann2, Jiří Vencovský6 and Michal Tomcik7, 1Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, 53rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 7Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

Meeting: ACR Convergence 2020

Keywords: Disease Activity, glucocorticoids, metabolic syndrome, Myopathies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by skeletal muscle and organ involvement and chronic course. Systemic inflammation, limited mobility, and glucocorticoid treatment can have a negative impact on intermediate metabolic pathways, especially on lipid metabolism. The aim of this study was to assess the differences in the lipid profile of IIM patients and healthy controls (HC) and the association with disease-specific features.

Methods: 133 patients with IIM (106 females; mean age 60.3; disease duration 2.2 years; DM 47 / PM 41 / IMNM 45) and 133 age-/sex-matched HC (106 females, mean age 60.2) without rheumatic diseases were included. Patients with DM and PM fulfilled the Bohan/Peter criteria for PM/DM and patients with IMNM fulfilled the ENMC criteria. Levels of selected parameters of lipid metabolism were measured in sera drawn after 8 hours of fasting by routine analytic methods. In IIM patients, disease activity, and damage were evaluated by MITAX and MDI, muscle involvement by manual muscle testing (MMT-8), and comorbidities of interest and current treatment were recorded. Data are presented as median (IQR).

Results: Several differences in disease activity, the dose of glucocorticoids, prevalence of comorbidities, and serum lipid levels were observed among the three subtypes of IIM (table 1). Lipid profile parameters, especially levels of negative cardiovascular predictive markers such as TC, TG, LDL-C, Apo-B, and the atherogenic index, were significantly higher compared to healthy controls. The most significant changes were observed in the IMNM group (compared to the corresponding age-/sex-matched HC) (table 2). Levels of TC, TG, LDL-C, apo-B and nonHDL negatively correlated with disease duration, but positively with laboratory markers of disease activity and the current prednisolone equivalent dose. Higher levels of HDL-C were associated with decreased levels of CRP, which is in line with the negative correlation of apo-A levels with CRP, CK, and myoglobin (table 3).

Conclusion: We have observed significant alterations in serum lipid parameters in our IIM patients compared to healthy age-/sex-matched individuals. Differences were also found among the three subtypes of IIM. These alterations were associated with laboratory parameters of disease activity and the current dose of corticosteroids. Acknowledgement: Supported by AZV NV18-01-00161A, MHCR-00023728, SVV-260373, and GAUK-312218.

Table 1: Baseline characteristics

Table 2: Lipidogram in IIM patients compared to healthy controls

Table 3: Correlation of lipid profile parameters and disease-specific features in all IIM patients (n=133)


Disclosure: S. Oreska, None; H. Storkanova, None; M. Spiritovic, None; B. Hermankova, None; M. Vrablik, None; K. Pavelka, AbbVie, 8, Merck Sharp & Dohme, 8, Bristol-Myers Squibb Company, 8, Roche, 8, Amgen, 8, Pfizer, 8, Novartis, 8, Egis, 8, Biogen, 8, UCB, 8; L. Šenolt, AbbVie, 2, 5, 8, Amgen, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 8, Merck Sharp and Dohme, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8, Takeda, 8; H. Mann, None; J. Vencovský, Eli Lilly, 5, 8, Abbvie, 5, 8, Boehringer, 5, Octapharma, 5, Sanofi, 8, Merck, 8, Biogen, 8, UCB Biopharma, 8, Roche, 8, Pfizer, 8; M. Tomcik, None.

To cite this abstract in AMA style:

Oreska S, Storkanova H, Spiritovic M, Hermankova B, Vrablik M, Pavelka K, Šenolt L, Mann H, Vencovský J, Tomcik M. Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/alterations-of-lipid-profile-in-iim-patients-are-associated-with-disease-activity-duration-and-glucocorticoid-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alterations-of-lipid-profile-in-iim-patients-are-associated-with-disease-activity-duration-and-glucocorticoid-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology